ERIKA SCANLON: Open Payments
NPI 1366712010 · BOSTON, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$290 in 11 payments from 7 companies in 2025. Trend: 2023 $141 · 2024 $586 · 2025 $290
Food & beverage: $290
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 2 | $53 |
| Alkermes, Inc. | 2 | $48 |
| E.R. Squibb & Sons, L.L.C. | 2 | $48 |
| Axsome Therapeutics, Inc. | 2 | $45 |
| ABBVIE INC. | 1 | $34 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $32 |
| Vanda Pharmaceuticals Inc. | 1 | $31 |
Products named: COBENFY, Auvelity, VRAYLAR, CAPLYTA, FANAPT, VIVITROL, REXULTI, ABILIFY MAINTENA.
Industry payments across MA — which companies pay providers there.
